Processa Pharmaceuticals Inc PCSA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.93 up $0.09, 4.89% at close Nov 6
Last close · Previous close $1.84
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$1.93up $0.41, 26.97%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.84Nov 5
- Volume8.42KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume189.43KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.04 to $8.88; now $1.93
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PCSA beat the S&P 500 in 1 of 6 periods.
| Period | PCSA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PCSA: up 27.0% S&P 500: down 5.6% | PCSA beat the S&P 500 by 32.6 percentage points Beat |
| 3M | PCSA: down 16.1% S&P 500: down 4.1% | PCSA trailed the S&P 500 by 12.0 percentage points Trailed |
| YTD | PCSA: down 33.0% S&P 500: up 8.7% | PCSA trailed the S&P 500 by 41.7 percentage points Trailed |
| 1Y | PCSA: down 75.6% S&P 500: up 10.9% | PCSA trailed the S&P 500 by 86.5 percentage points Trailed |
| Long term | ||
| 3Y | PCSA: down 99.0% S&P 500: up 75.0% −78.5% vs +20.5% a year | PCSA trailed the S&P 500 by 174.0 percentage points Trailed |
| 5Y | PCSA: down 99.9% S&P 500: up 67.8% −77.7% vs +10.9% a year | PCSA trailed the S&P 500 by 167.7 percentage points Trailed |
$10,000 invested in PCSA 5 years ago (Nov 5, 2021) would be worth about $6 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
PCSA beat the S&P 500 in 1 of 6 periods.
| Period | PCSA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PCSA: up 27.0% S&P 500: down 5.6% | PCSA beat the S&P 500 by 32.6 percentage points Beat |
| 3M | PCSA: down 16.1% S&P 500: down 4.3% | PCSA trailed the S&P 500 by 11.8 percentage points Trailed |
| YTD | PCSA: down 33.0% S&P 500: up 7.8% | PCSA trailed the S&P 500 by 40.8 percentage points Trailed |
| 1Y | PCSA: down 75.6% S&P 500: up 9.7% | PCSA trailed the S&P 500 by 85.3 percentage points Trailed |
| Long term | ||
| 3Y | PCSA: down 99.0% S&P 500: up 68.8% −78.5% vs +19.1% a year | PCSA trailed the S&P 500 by 167.8 percentage points Trailed |
| 5Y | PCSA: down 99.9% S&P 500: up 56.9% −77.7% vs +9.4% a year | PCSA trailed the S&P 500 by 156.8 percentage points Trailed |
$10,000 invested in PCSA 5 years ago (Nov 5, 2021) would be worth about $6 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$9,000.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Oct 10, 2017.
Stock splits
2
Latest: 1-for-25 on . Share counts adjust after each split.
Both splits
- 1-for-25
- 1-for-20
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$13.44M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$3.38M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$2.73M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$2.83M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$3.93M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$3.44M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$3.36M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$3.38M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$3.27M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$11.43M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$27.42M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$11.12M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$11.85M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$13.56M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$11.97MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$11.97MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $6.40MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $668.33KAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$668.33KAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.87As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −394.2%Last 12 months
Over the last 12 months, Processa Pharmaceuticals lost money: its net loss was 394.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −244.5%Last 12 months
Over the last 12 months, Processa Pharmaceuticals’s net loss was 244.5% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Processa Pharmaceuticals Inc
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Maryland, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PCSA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PCSA stock FAQ
What is PCSA stock’s price today?
Processa Pharmaceuticals (PCSA) traded at $1.93 at the close on , up $0.09 (4.89%) from the previous close of $1.84. Over the past 52 weeks it has traded between $1.04 and $8.88.
If you invested $1,000 in PCSA 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PCSA on would be worth about $1 at the close on , a total return of −99.9%. The same $1,000 would be worth $244 if invested one year ago. Past performance doesn’t predict future returns.
Does PCSA pay a dividend?
Processa Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is PCSA’s 52-week high and low?
Over the past 52 weeks PCSA has traded as low as $1.04 and as high as $8.88. At $1.93 at the close on , it is 78.3% below that high and 85.4% above the low.
What is PCSA’s all-time high?
PCSA’s highest closing price was $9,000.00 on , adjusted for stock splits. At $1.93 at the close on , it is 100.0% below that record.
Has PCSA stock ever split?
Yes, twice: 1-for-20 on ; 1-for-25 on .
How has PCSA stock performed?
Including dividends and measured to the close on , PCSA has returned −33.0% so far this year and −75.6% over the past year, and −99.9% over five years (−77.7% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Processa Pharmaceuticals in?
Processa Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in Maryland, USA.
What exchange does PCSA trade on?
Processa Pharmaceuticals trades on the Nasdaq under the ticker symbol PCSA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.